Do Contact Precautions Reduce the Incidence of Intensive Care Unit-Acquired Pseudomonas aeruginosa Infections? The DPCPYO (Detection and Contact Precautions for Patients With P. aeruginosa) Cluster-Randomized Crossover Trial
| dc.rights.license | open | en_US |
| dc.contributor.author | SLEKOVEC, Celine | |
| dc.contributor.author | ROBERT, Jerome | |
| dc.contributor.author | BERTHELOT, Philippe | |
| dc.contributor.author | VAN DER MEE-MARQUET, Nathalie | |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| dc.contributor.author | ROGUES, Anne-Marie | |
| dc.contributor.author | DEROUIN, Veronique | |
| dc.contributor.author | CHOLLEY, Pascal | |
| dc.contributor.author | BERTRAND, Xavier | |
| dc.contributor.author | GBAGUIDI-HAORE, Houssein | |
| dc.contributor.author | GROUP, Dpcpyo Trial | |
| dc.date.accessioned | 2022-01-17T10:57:12Z | |
| dc.date.available | 2022-01-17T10:57:12Z | |
| dc.date.issued | 2021-11-02 | |
| dc.identifier.issn | 1537-6591 (Electronic) 1058-4838 (Linking) | en_US |
| dc.identifier.uri | https://oskar-bordeaux.fr/handle/20.500.12278/124406 | |
| dc.description.abstractEn | BACKGROUND: The issue of contact precautions as contributory factors for reducing Pseudomonas aeruginosa (Pa) infections in intensive care units (ICUs) remains questioned. We evaluated the impact of the addition of contact precautions to standard precautions for Pa-positive patients on incidence of ICU-acquired Pa infections. METHODS: In this multicenter, cluster-randomized crossover trial, 10 French ICUs were randomly assigned (1:1) to sequence 0-1 (6-month control period [CP]/3-month washout period/6-month intervention period [IP]) or sequence 1-0 (6-month IP/3-month washout period/6-month CP). A surveillance screening program for Pa was implemented. Competing-risks regression models were built with death and discharge without the occurrence of ICU-acquired Pa infection (the primary outcome) as competing events. Models were adjusted for within-ICU correlation and patient- and ICU-level covariates. The Simpson diversity index (SDI) and transmission index (TI) of Pa isolates were derived from pulsed-field gel electrophoresis typing. RESULTS: Within recruited ICUs, the cumulative incidence and incidence rate of ICU-acquired Pa infections were 3.38% (55/1625) versus 3.44% (57/1658) and 3.31 versus 3.52 per 1000 patient-days at risk during the CP and IP, respectively. Multivariable models indicated that the intervention did not significantly change the cumulative incidence (subdistribution hazard ratio, .91; 95% confidence interval [CI], .49-1.67; P = .76) or rate (cause-specific hazard ratio, 1.36; 95% CI, .71-2.63; P = .36) of the primary outcome. SDI and TI did not significantly differ between CP and IP. CONCLUSIONS: The addition of contact precautions to standard precautions for Pa-positive patients with a surveillance screening program does not significantly reduce ICU-acquired Pa infections in non-outbreak situations. Clinical Trials Registration. ISRCTN92710225. | |
| dc.language.iso | EN | en_US |
| dc.subject.en | Contact precautions | |
| dc.subject.en | Pseudomonas aeruginosa | |
| dc.subject.en | ICU | |
| dc.subject.en | Patient-to-patient transmission | |
| dc.subject.en | PFGE | |
| dc.title.en | Do Contact Precautions Reduce the Incidence of Intensive Care Unit-Acquired Pseudomonas aeruginosa Infections? The DPCPYO (Detection and Contact Precautions for Patients With P. aeruginosa) Cluster-Randomized Crossover Trial | |
| dc.type | Article de revue | en_US |
| dc.identifier.doi | 10.1093/cid/ciaa1663 | en_US |
| dc.subject.hal | Sciences du Vivant [q-bio]/Santé publique et épidémiologie | en_US |
| dc.identifier.pubmed | 33137174 | en_US |
| bordeaux.journal | Clinical Infectious Diseases | en_US |
| bordeaux.page | e2781-e2788 | en_US |
| bordeaux.volume | 73 | en_US |
| bordeaux.hal.laboratories | Bordeaux Population Health Research Center (BPH) - UMR 1219 | en_US |
| bordeaux.issue | 9 | en_US |
| bordeaux.institution | Université de Bordeaux | en_US |
| bordeaux.institution | INSERM | en_US |
| bordeaux.team | PharmacoEpi-Drugs | en_US |
| bordeaux.peerReviewed | oui | en_US |
| bordeaux.inpress | non | en_US |
| hal.export | false | |
| dc.rights.cc | Pas de Licence CC | en_US |
| bordeaux.COinS | ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Clinical%20Infectious%20Diseases&rft.date=2021-11-02&rft.volume=73&rft.issue=9&rft.spage=e2781-e2788&rft.epage=e2781-e2788&rft.eissn=1537-6591%20(Electronic)%201058-4838%20(Linking)&rft.issn=1537-6591%20(Electronic)%201058-4838%20(Linking)&rft.au=SLEKOVEC,%20Celine&ROBERT,%20Jerome&BERTHELOT,%20Philippe&VAN%20DER%20MEE-MARQUET,%20Nathalie&ROGUES,%20Anne-Marie&rft.genre=article |
Fichier(s) constituant ce document
| Fichiers | Taille | Format | Vue |
|---|---|---|---|
|
Il n'y a pas de fichiers associés à ce document. |
|||